PFE Pfizer
- 27.700
- +0.520+1.91%
- 27.810
- +0.110+0.40%
Pfizer News
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
Pfizer Analyst Ratings
Major Bank Ratings | J.P. Morgan Chase: Pfizer's sales of core products in the first quarter met expectations and maintained a “neutral” rating
Pfizer Exceeds Q1 Expectations With Strong Earnings and Raises 2024 Guidance: A Buy Rating by Evan Seigerman
Leerink Adjusts Price Target on Pfizer to $29 From $27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating
Pfizer (PFE) Receives a Hold From Barclays
Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings
Jefferies Remains a Buy on Pfizer (PFE)
Analysts Offer Insights on Healthcare Companies: SurModics (SRDX) and Pfizer (PFE)
UBS Reaffirms Their Hold Rating on Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
Cantor Fitzgerald Corp.: Reiterates the Pfizer (PFE.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of 45.00 US dollars.
Pfizer Analyst Ratings
Pfizer Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)
Pfizer's Hold Rating Upheld Amid Modest Sales Outperformance and Market Uncertainty
Pfizer (PFE) Receives a Hold From Berenberg Bank
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Fusion Pharmaceuticals (FUSN)
Analysis
Price Target
No Data
